Twinpig Biolab, Inc.

Twinpig Biolab, Inc. is a South Korean biopharmaceutical company specializing in tumor microenvironment editing and advanced drug delivery solutions for oncology applications. Founded in 2019 and headquartered in Seoul, South Korea, Twinpig Biolab, Inc. focuses on the development of biopharmaceutical solutions.

The company has raised a total of KRW 1. 5 billion across multiple funding rounds, with the latest funding round conducted in November 2025 led by Scale Up Partners. The firm has successfully completed five deals to date. Twinpig Biolab, Inc.

specializes in advanced biopharmaceutical solutions focused on tumor microenvironment (TME) editing and innovative drug delivery systems. Its core offerings include targeted therapies aimed at removing tumor-promoting cells and regulating the activity of specific TME constituents such as tumor-associated macrophages (TAM), cancer-associated fibroblasts (CAF), and myeloid-derived suppressor cells (MDSC). The company's proprietary technology utilizes nanoparticle drug delivery systems that encapsulate various therapeutic agents, including mRNA, siRNA, peptides, and small molecules. These products specifically target the unique cellular environments that facilitate tumor growth and progression, serving hospitals, research institutions, and pharmaceutical companies in North America, Europe, and Asia.

Twinpig Biolab generates revenue through strategic partnerships and collaborations with research institutions and pharmaceutical companies for the development and commercialization of its innovative therapies. Its revenue model is based on B2B transactions, supplying proprietary drug delivery systems and TME-targeting therapies to its partners, structured around milestone payments and royalty agreements that depend on successful clinical outcomes. These multi-year agreements typically include development fees and revenue-sharing arrangements once products are launched, aligning the interests of both Twinpig Biolab and its partners in advancing cancer treatment solutions. In November 2025, Twinpig Biolab raised KRW 1.

5 billion in venture funding from returning investor Scale Up Partners. The company will utilize these funds primarily for research and development initiatives and to advance its pharmaceuticals to meet international standards. Twinpig Biolab is also focused on expanding into new markets and geographic regions, particularly targeting North America and Europe, with potential product launches slated for 2026.